Grabar Law Office

Grabar Law Office is investigating potential antitrust claims on behalf of all direct purchasers of PVC Pipes since April 1, 2021. Did you or your company purchase PVC Pipes directly from a PVC Pipe Manufacturer since April 1, 2021? It is alleged that PVC Pipe manufacturers used a shared industry newsletter, OPIS, to coordinate pricing actions and fix the price of PVC Pipes sold in the United States and its territories, even as demand and key raw material costs declined. The alleged price-fixing scheme has resulted in massively inflated PVC Pipe prices and profit margins. Learn more at: https://lnkd.in/eCppf4Ns

Grabar Law Office In the News:  Biotech Execs Face Investor Suit Over Medicare Claims Executives and directors of biopharmaceutical company Ardelyx have been hit with a shareholder derivative suit in Massachusetts federal court alleging the company misled investors over its intentions and ability to apply for a Medicare reimbursement program for its kidney disease treatment. According to the complaint filed on Friday, Ardelyx obtained approval to distribute Xphozah, an oral therapy used to treat adults with chronic kidney disease on dialysis, in October 2023. It is alleged that Ardelyx misled investors about its plan to apply for a program under which the Medicare and Medicaid programs would pay for Xphozah, telling investors that the successful distribution of the drug would depend in part on its inclusion in the program. https://lnkd.in/eXg4uAA4

Grabar Law Office is investigating potential antitrust claims on behalf of all direct purchasers of PVC Pipes since April 1, 2021. Did you or your company purchase PVC Pipes directly from a PVC Pipe Manufacturer since April 1, 2021? It is alleged that PVC Pipe manufacturers used a shared industry newsletter, OPIS, to coordinate pricing actions and fix the price of PVC Pipes sold in the United States and its territories, even as demand and key raw material costs declined. The alleged price-fixing scheme has resulted in massively inflated PVC Pipe prices and profit margins. Learn more at: https://lnkd.in/eCppf4Ns

GRABAR LAW OFFICE IN THE NEWS: UNITEDHEALTH BRASS FACE INVESTOR SUIT OVER MERGER PROBE Executives and directors of UnitedHealth Group were hit with a shareholder derivative suit alleging they concealed that the U.S. Department of Justice reopened an antitrust investigation into the health insurance giant following its acquisition of a healthcare data company and that its brass knowingly sold more than $100 million of shares before the information was publicly revealed. See https://lnkd.in/eaEy4_q8

Happy 4th of July from Grabar Law Office! Wishing you a joyous Independence Day filled with pride, honor, and celebration. As we commemorate our nation's freedom, we extend our heartfelt gratitude to those who have served and continue to protect our liberty. May your day be filled with joy, family, friends, and fireworks!

GRABAR LAW OFFICE INVESTIGATES UNLAWFUL OVERCHARGES ON BEHALF OF DIRECT PURCHASERS OF HILL-ROM HOSPITAL BEDS, BIRTHING BEDS, AND ICU BEDS   Did You Purchase a Hospital Bed Directly from Hill-Rom Within the Past 4 Years? Grabar Law Office is investigating potential antitrust claims on behalf of all direct purchasers of Standard Hospital Beds, ICU Beds, and/or Birthing Beds from Hill-Rom during the past 4 years. According to a recently filed antirust class action complaint, it is alleged that Hill-Rom, a subsidiary of Baxter International Inc. (NYSE: BAX), on or about January 1, 2013, began a systematic effort to exclude unlawfully competition and increase its hospital bed prices. It is alleged that by unlawfully exploiting its monopoly power to exclude competition, Hill-Rom has foreclosed would-be rivals from being able to discipline Hill-Rom’s monopoly power and pricing, and thereby Hill-Rom has been able to charge, and has charged, supracompetitive prices to similarly situated hospitals for hospital beds. To learn more visit: https://lnkd.in/e3AtgEiq

Dollar General executives and directors were hit with a shareholder derivative suit alleging they downplayed staffing struggles and disarray in the retailer's stores, which resulted in a buildup of unwanted inventory and government investigations. It is alleged in Tennessee federal court that Dollar General failed to address logistics problems within its stores, including chronic understaffing and cluttered shelves, and also faced investigations in Ohio, Arizona, Louisiana, Mississippi and North Carolina for allegedly charging higher-than-advertised prices. "As a result of chronic understaffing, employees lacked sufficient time to update merchandise pricing or deal with inventory issues as they arose, especially as the growing inventory on store shelves began piling up, leading to crowded isles and disorganized shelves," the suit states. "These practices resulted in an uninviting shopping environment which dissuaded consumers from patronizing Dollar General stores."   Dollar General failed to warn investors that it was not working on fixing inventory issues within its stores, and that it was facing regulatory scrutiny across several states. https://lnkd.in/eKJsmYqh

Grabar Law Office In The News: SolarEdge Hit With Derivative Suit Over 2023 Earnings Miss https://lnkd.in/enhAbHX2

ATTENTION LONG-TERM SHAREHOLDERS OF CUMMINS INC. (NYSE: CMI) Grabar Law Office is investigating claims on behalf of Cummins shareholders. The investigation concerns whether certain officers and directors of Cummins have breached their fiduciary duties owed to the company. Why: On January 10, 2024, the Department of Justice and State of California announced that diesel engine manufacturer Cummins agreed to pay a record $1.675 billion civil penalty for vehicle emissions test cheating. In addition, a securities fraud class action complaint has been filed that further alleges that Cummins, via certain of its officers and directors, made materially false and/or misleading statements and/or failed to disclose that: (1) Contrary to its post-April 2019 Announcement assurances about its commitment to compliance, Cummins continued to produce engines with unlawful emission defeating devices from 2019 to 2023; (2) accordingly, Cummins understated its legal and regulatory risk, and overstated its commitment to environmental protection; and (3) as a result, Cummins’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. What to do: If you are a current Cummins shareholder who has held Cummins shares since prior to April 30, 2019, and you would like to participate or learn more about this matter at no cost to you, you are encouraged to visit https://lnkd.in/edK5ny98, contact Joshua H. Grabar at [email protected] or Mia R. Heller at [email protected], or call us at 267-507-6085. $CMI #cummins Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]

NOTICE TO LONG-TERM FMC CORPORATION (NYSE: FMC) INVESTORS Grabar Law Office is investigating claims on behalf of FMC (NYSE: FMC) shareholders. The investigation concerns whether certain officers of FMC have breached their fiduciary duties owed to the company. Shareholders who have held FMC stock since prior to before November 2, 2022 should click here: https://lnkd.in/esp3NTtK. You can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. A recently filed securities fraud class action complaint alleges that FMC Corporation, via certain of its officers and directors, made materially false and/or misleading statements about the Company's business, operations, and prospects including that: (1) the diminishment of patent protection for FMC's flagship products, such as diamides (a class of insecticide), which accounted for almost 40% of FMC’s revenues in the past year and an estimated 60+% of reported EBITDA, following legal defeats in key markets including India, China, and Brazil had opened the door to increased competition from generic versions of those products; (2) the Company repeatedly mislead investors about the status of such proceedings and falsely claimed that it did not and would not face generic competition in key markets until 2026 at the earliest; and (3) because of these issues FMC's positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you have have held FMC stock since prior to November 2, 2022 and would like to learn more about this matter, you are encouraged to visit https://lnkd.in/esp3NTtK contact Josh Grabar at [email protected], or Mia Heller at [email protected], or call 267-507-6085. #FMC $FMC   Attorney Advertising Disclaimer   Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]